Lipid Metabolism in Renal Transplant Patients Receiving Tacrolimus/Sirolimus Combination Therapy
| Autor: | Zbigniew Wlodarczyk, Kaija Salmela, Raimund Margreiter, Z Czajkowski, Stefan Vitko |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Hypercholesterolemia Urology chemical and pharmacologic phenomena Tacrolimus chemistry.chemical_compound stomatognathic system Pharmacokinetics Humans Medicine Triglycerides Antibacterial agent Sirolimus Transplantation Triglyceride Cholesterol business.industry Mycophenolic Acid medicine.disease Surgery Calcineurin stomatognathic diseases chemistry Drug Therapy Combination business Immunosuppressive Agents Dyslipidemia Follow-Up Studies medicine.drug |
| Zdroj: | Transplantation Proceedings. 37:1871-1873 |
| ISSN: | 0041-1345 |
| DOI: | 10.1016/j.transproceed.2005.03.152 |
| Popis: | Introduction. The administration of sirolimus has been reported to be associated with high serum cholesterol and high triglyceride values. In a large prospective, multicenter 6-month study in renal transplantation, basic parameters of lipid metabolism (total serum cholesterol and triglycerides) were systematically assessed in patients who received tacrolimus/mycophenolate mofetil/steroids (Tac/MMF), tacrolimus/0.5 mg sirolimus (SIR)/steroids (Tac/0.5SIR) on tacrolimus/2 mg sirolimus/steroids (Tac/2SIR). Methods. For purposes of analysis, lipid parameters were classified using the National Kidney Foundation Dyslipidemia Classification definitions. Results. Complete sets of data at all visits (baseline, months 1, 3, and 6) were available for 211 Tac/MMF, 210 Tac/0.5SIR, and 203 Tac/2SIR patients. Total serum cholesterol in the Tac/MMF group was 193.4 at baseline and 202.9 mg/dL at month 6. Values increased from 196 mg/dL to 212.5 mg/dL in Tac/0.5SIR and from 200 mg/dL to 230.5 mg/dL in Tac/2SIR. Differences in parameters between treatment groups were statistically significant (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect